UNSPSC 51102819: Betamethasone/clotrimazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102819 Betamethasone/clotrimazole is a Commodity code that in practice captures state and local procurement of pharmaceutical products and medical supplies far broader than the code's nominal specificity suggests. Recent opportunities show state and local bodies soliciting generic multi-source pharmaceuticals, over-the-counter products, emergency medical supplies, and pharmacy benefit management services — not betamethasone/clotrimazole formulations alone. The issuing bodies span state health and human services agencies, cooperative purchasing alliances, county health departments, and municipal fire and emergency services. Scope of work ranges from routine stocking of emergency medical consumables (bandaging, respiratory equipment, cardiac monitoring devices) to strategic pharmacy benefit program design and direct-to-manufacturer prescription sourcing. Insurance, compliance, and supply-chain security requirements are standard, including FDA certification, cGMP compliance, Drug Supply Chain Security Act adherence, and expiration-date minimums. Awarded vendors typically work through authorized wholesalers or direct delivery models with quarterly or on-demand fulfillment.

Geographic activity concentrates in Florida, Texas, and Minnesota, with multistate cooperative purchasing vehicles amplifying reach. Representative recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026; 1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023), the City of Tampa Fire Department's IFB for medical and first aid supplies (posted March 25, 2026; 169 line items including respiratory equipment and cardiac devices, due March 13, 2026; $700,000 estimated value with a 5% small local business enterprise bid discount), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026; proposals due March 26, 2026; serving Minnesota and Oregon with mandatory wholesaler partnerships), and the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs (posted April 3, 2026; due April 3, 2026; exploratory market-intelligence phase). The code shows active state and local procurement across health, emergency services, and cooperative purchasing channels.